Last Updated: November 9, 2026

Patent: 7,449,184

Summary for Patent: 7,449,184

Title:	Fixed dosing of HER antibodies
Abstract:	The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.
Inventor(s):	Allison; David E. (San Mateo, CA), Bruno; Rene (Marseilles, FR), Lu; Jian-Feng (Foster City, CA), Ng; Chee M. (San Mateo, CA)
Assignee:	Genentech, Inc. (South San Francisco, CA)
Application Number:	11/154,091
Patent Claims:	see list of patent claims

Details for Patent 7,449,184

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	September 25, 1998	⤷ Start Trial	2025-06-15
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	February 10, 2017	⤷ Start Trial	2025-06-15
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	February 26, 2004	⤷ Start Trial	2025-06-15
Genentech, Inc.	PERJETA	pertuzumab	Injection	125409	June 8, 2012	⤷ Start Trial	2025-06-15
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	February 28, 2019	⤷ Start Trial	2025-06-15
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.